FARMAMICO is an easy-to-use app that was born as an evolution of the Farmamico project and summarizes the main interactions of dicumarin oral anticoagulants: Warfarin, Acenocoumarol and NAOs (New Oral Anticoagulants) currently available: Apixaban, Dabigatran, Rivaroxaban, Edoxaban.
It is important to know that the probability of an interaction occurring must not be an obstacle to the administration of necessary therapies, the absolute contraindication is in fact very rare. Instead, it is essential that the patient warns the doctor of all drugs taken (including unconventional therapies such as supplements, herbal products and folk medicine products), for an assessment of the risk / benefit ratio and appropriate monitoring.
Guide to using the APP
This application reports the clinical relevance, the possible effects, the interaction mechanism and the clinical behavior that derives primarily from the technical data sheet (CPR) of the anticoagulant and from Micromedex. The sources used are technical data sheet (RCP), Micromedex, Codifa and ERHA 2018 Practical Guide on the use of DOACs.
In particular, a drug or product is reported as interacting when present in at least one of the 3 sources mentioned (in order of evidence: RCP, Micromedex, Codifa and EHRA practical guide).
When there are several medicinal specialties for the same active ingredient, only a few names have been entered, by way of example. Also included are foods, alcohol and herbal medicines, with indication of the Latin name and the botanical family and the Italian and English name. For topical formulations, the risk of interactions is not always specified in the SmPC, even if reported in the literature for PA.
The realization and the contents are the property and responsibility of the Spedali Civili of Brescia. The sources from which the application draws are constantly updated, including with the EHRA 2021 practical guide. Any reports can be sent to the email address: pharmacy.farmacovigilanza@asst-spedalicivili.it
It is important to know that the probability of an interaction occurring must not be an obstacle to the administration of necessary therapies, the absolute contraindication is in fact very rare. Instead, it is essential that the patient warns the doctor of all drugs taken (including unconventional therapies such as supplements, herbal products and folk medicine products), for an assessment of the risk / benefit ratio and appropriate monitoring.
Guide to using the APP
This application reports the clinical relevance, the possible effects, the interaction mechanism and the clinical behavior that derives primarily from the technical data sheet (CPR) of the anticoagulant and from Micromedex. The sources used are technical data sheet (RCP), Micromedex, Codifa and ERHA 2018 Practical Guide on the use of DOACs.
In particular, a drug or product is reported as interacting when present in at least one of the 3 sources mentioned (in order of evidence: RCP, Micromedex, Codifa and EHRA practical guide).
When there are several medicinal specialties for the same active ingredient, only a few names have been entered, by way of example. Also included are foods, alcohol and herbal medicines, with indication of the Latin name and the botanical family and the Italian and English name. For topical formulations, the risk of interactions is not always specified in the SmPC, even if reported in the literature for PA.
The realization and the contents are the property and responsibility of the Spedali Civili of Brescia. The sources from which the application draws are constantly updated, including with the EHRA 2021 practical guide. Any reports can be sent to the email address: pharmacy.farmacovigilanza@asst-spedalicivili.it
Show More
